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Introduction
Knowledge of the regulatory mechanisms underlying cardiac
development is essential for understanding the molecular
basis of congenital heart defects. During embryonic heart
development, differentiation of cardiac muscle is regulated by
interactions between a surprisingly large number of cardiac-
restricted transcription factors. For example, the homeodomain
transcription factor Nkx2-5 binds directly to the promoters of
several cardiac differentiation genes (Chen and Schwartz,
1995; Durocher et al., 1997; Molkentin et al., 2000). However,
Nkx2-5 is a relatively weak transcriptional activator and
efficient transcription from its target promoters is dependent on
the presence of additional regulatory factors. Proteins that
interact with Nkx2-5 include the zinc finger transcription factor
Gata4 (Durocher and Nemer, 1998; Sepulveda et al., 1998) the
T box-containing proteins, Tbx5 and Tbx20 (Bruneau et al.,
2001; Stennard et al., 2003) and the homeodomain protein
Pitx2 (Ganga et al., 2003). Additional transcription factors,
many of which are not cardiac specific, are also essential for
embryonic heart development. These include the nuclear factor
of activated T cell (NFAT) family of factors (Schubert et al.,
2003; Bushdid et al., 2003) and the myocyte enhancer factor 2
(MEF2) family of transcription factors (Molkentin and
Markham, 1993; Kuisk et al., 1996; Lin et al., 1997). Each of
these proteins are believed to interact with other cardiac
transcription factors to control cardiac gene expression (Wada
et al., 2002; Black and Olson, 2003).
Numerous cardiac genes also contain binding sites for the
ubiquitous transcription factor, serum response factor (SRF).
The SRF binding site (the CArG box) has been demonstrated
to be essential for myocardial expression of a number of genes
including cardiac α-actin (Belaguli et al., 2000; Latinkic et al.,
2002), atrial natriuretic factor (Argentin et al., 1994; Small and
Krieg, 2003) and the sodium calcium exchanger (Cheng et al.,
1999). The presence of CArG elements is not unique to cardiac
promoters, however, as binding sites are also common in
skeletal and smooth muscle gene promoters, as well as in the
control regions of growth factor-inducible genes. Recent
studies have shown that SRF activates transcription of smooth
and cardiac muscle promoters in collaboration with myocardin,
a cofactor that associates directly with SRF but does not bind
DNA (Wang et al., 2001). Since myocardin is expressed in
cardiac and smooth muscle, but not in skeletal muscle,
interactions between myocardin and SRF may provide the
mechanism by which cardiac and smooth muscle-specific
promoters are distinguished from skeletal muscle promoters.
Recent studies have emphasized the role of myocardin as a
powerful activator of smooth muscle genes (Chen et al., 2002;
Du et al., 2003; Wang et al., 2003) and the mouse knockout of
myocardin results in embryonic death due to absence of
vascular smooth muscle differentiation (Li et al., 2003). In
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many respects therefore, myocardin has the properties of a
master regulator of smooth muscle development.
The lack of a cardiac phenotype in myocardin knockout
mice is seemingly at odds with our previous studies which
showed that expression of a dominant negative of myocardin
in Xenopus embryos was able to abolish cardiac gene
expression, suggesting an important role for myocardin in heart
development (Wang et al., 2001). However, a caveat in the
interpretation of such dominant negative experiments is that
such mutants can interfere with multiple transcriptional
regulators. It has been proposed that redundant activities of the
myocardin-related factors, MRTF-A and MRTF-B (Wang et
al., 2002) may be sufficient to rescue heart development in
myocardin mutant embryos but this possibility has not yet been
addressed experimentally.
In this study, we show that myocardin is able to activate a
large number of cardiac and smooth muscle differentiation
genes in non-muscle cells. We also show that myocardin can
function combinatorially with another cardiac-expressed
transcription factor, Gata4, to achieve efficient transcription of
cardiac differentiation markers. Conversely, depletion of
myocardin in the developing embryo by antisense morpholino
injection abolishes cardiac marker gene expression, indicating




Xenopus laevis embryos were staged according to Nieuwkoop and
Faber (Nieuwkoop and Faber, 1994). Xenopus eggs were in vitro
fertilized, dejellied using 2% L-cysteine (pH 8.0), and maintained in
0.2× MMR (Marc’s Modified Ringers). Targeted mRNA injections
were performed in 0.4× MMR/4% Ficoll at the 8-cell stage. Different
mRNAs (125 pg, 250 pg or 400 pg) were injected in a volume of 4.6
nl. Embryos were cultured in 0.2× MMR until a suitable stage and
fixed in MEMPFA for assay by in situ hybridization. In animal cap
assays embryos were injected at the one-cell stage into the animal
pole. Animal pole explants were dissected from mRNA-injected or
uninjected control embryos at stage 8 in 1× NAM (Normal Amphibian
Medium). Caps were cultured in 0.5× NAM containing gentamycin
until the equivalent of stage 12.5 and RNA was extracted for RT-PCR
analysis.
Xenopus laevis transgenesis
The NβT promoter driven myocardin or GFP transgene was linearized
with PmeI and transgenic Xenopus embryos were generated using
previously described methods (Kroll and Amaya, 1996; Sparrow et
al., 2000; Small and Krieg, 2003). Double transgenics were made
using the NβT-GFP and NβT-myocardin constructs, and GFP
expression in neural tissues was used as a control for transgenesis.
Whole-mount in situ hybridization
Whole-mount in situ hybridization was carried out using a
modification of the protocol of Harland (Harland, 1991), using
antisense digoxigenin-labeled probes transcribed using a MEGAscript
kit (Ambion). For serial sections, embryos were post-fixed in 4%
paraformaldehyde for 6 hours at room temperature and embedded in
Paraplast. Transverse sections (10 µm) were cut on a microtome.
Cloning of Xenopus laevis myocardin
RT-PCR using degenerate primers designed against the conserved
amino acid regions WETMEWL and IFNIDF within the human and
mouse myocardin sequences was performed using random-primed
adult Xenopus heart cDNA. After cloning and sequencing of the
resulting 99 bp fragment, the remaining portions of the myocardin
cDNA were amplified by 5′ and 3′ RACE using Xenopus heart cDNA
prepared according to the manufacturer’s instructions (FirstChoice
RLM-RACE Kit; Ambion). The final Xenopus myocardin sequence
was determined by PCR amplification, cloning and sequencing of the
entire myocardin coding region using the Expand High Fidelity PCR
System (Roche).
RT-PCR of marker gene expression
Ten animal cap explants were harvested for each sample and RNA
was isolated using buffer A/proteinase K. cDNA was prepared from
one half of each RNA sample, and a minus RT negative control sample
was prepared from the remaining RNA. One fiftieth of the cDNA
sample was used as template in radioactive RT-PCR that included
0.3 µCi of α-32P in a 20 µl reaction. RT-PCR cycle number was
determined to assure the reaction was in the linear range of
amplification. PCR samples were separated on non-denaturing 5%
acrylamide gels.
Primers
Primers used were as follows: calponin H1, 5′-GCACTGTACGGAA-
GATCAACG-3′ (forward) and 5′-CGATATCCACTCTGGCACCTT-
3′ (reverse) (Tm=60°C); cardiac α actin (Niehrs et al., 1994)
(Tm=63°C); cTnI (Vokes and Krieg, 2002) (Tm=63°C); Gata4, 5′-
TCTGGCCACAACATGTGG-3′ (forward) and 5′-CAGTTGACA-
CATTCTCGG-3′ (reverse) (Tm=56°C); Mef2A, 5′-CAGCTC-
CAGCAGTTCCTAT-3′ (forward) and 5′-TTACACTGAGGCCTAAT-
GCA3′ (reverse) (Tm=56°C); MHCα, 5′-ACCAAGTACGAGACT-
GACGC-3′ (forward) and 5′-CTCTGACTTCAGCTGGTTGA-3′
(reverse) (Tm=60°C); MLC2, 5′-GAGGCATTCAGCTGTATCGA-3′
(forward) and 5′-GGACTCCAGAACATGTCATT-3′ (reverse) (Tm=
60°C); MRF4, 5′-ATCAGCAGGACAAGCCACAGA-3′ (forward)
and 5′-TGTATAGTGCAAGGGTGCCTG-3′ (reverse) (Tm=58°C);
MRTF-A, 5′-TGAGGGTAAGCAAAAATTAAG-3′ (forward) and 5′-
GGTGAACTGAAGTGCCATAGA-3′ (reverse) (Tm=60°C); MRTF-
B, 5′-TTGGGTGCATAGCTGGAACT-3′ (forward) and 5′-CCAAG-
CATCATCCTGTGTTAC-3′ (reverse) (Tm=60°C); Myf5, 5′-CAT-
GTCTAGCTGTTCAGATGG-3′ (forward) and 5′-CAATCATGCG-
CATCAGGTGAC-3′ (reverse) (Tm=58°C); MyoD, 5′-AACTGCTC-
CGATGGCATGATGGATTA-3′ (forward) and 5′-ATTGCTGGGA-
GAAGGGATGGTGATTA-3′ (reverse) (Tm=60°C); myocardin, 5′-
GCCCAAAGCAAATTACAAGAA-3′ (forward) and 5′-GGAAG-
TCGGTGTTGAAGATAC-3′(reverse) (Tm=60°C); myogenin, 5′-
CCTGAATGGAATGACTCTGAC-3′ (forward) and 5′-GGCA-
GAAGGCATTATATGGAA-3′ (reverse) (Tm=58°C); Nkx2-5, 5′-
TCTGAACTCACTGAGGAA-3′ (forward) and 5′-AGGACTG-
GTACAGCTATC-3′ (reverse) (Tm=56°C); ODC (Bouwmeester et
al., 1996) (Tm=64°C); SkMLC, 5′-TGGTCAAAGAGGCATCTG-
GA-3′ (forward) and 5′-AGTTGTGTCTCTGATGGGATG-3′
(reverse) (Tm=60°C); SM22, 5′-TCCAGACAGTAGACCTGTATG-3′
(forward) and 5′-GTCGACCGTATCCTGTCATC-3′ (reverse)
(Tm=60°C); SM actin, 5′-ACCACTTACAACAGCATCATG-3′
(forward) and 5′-ACCAATCCAGACGGAGTACTT-3′ (reverse)
(Tm=60°C); SRF, 5′-TGCACTGTGCCTGTGTGATTA-3′ (forward)
and 5′-CAGACTCACACAACTTGCACA-3′ (reverse) (Tm=58°C);
Xbra (Vokes and Krieg, 2002) (Tm=60°C).
Myocardin loss of function by morpholino oligonucleotide
injection
Antisense morpholinos (MO1 5′-CAGCTTTTCTGGTTTAAT-
GGTTTAT-3′ and MO2 5′-TGTTCGGAACCCAAGAGAGTCATGT-
3′) were directed against two independent sequences near the 5′ end
of the myocardin transcript. The morpholinos were targeted to
sequences that are identical in the A and B copies of the Xenopus
laevis genes in order to inhibit translation of both mRNAs. A dose
curve was determined with 2.5 ng, 5 ng, 10 ng and 20 ng of
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morpholino, injected in one cell of a two-cell embryo so the
uninjected side served as a negative control. A concentration-
dependent phenotype was observed with an increasing percentage of
asymmetric cardiac gene expression with increasing dose. MO-treated
embryos were assayed using in situ hybridization and appropriate
marker probes.
Results
Cloning and expression of Xenopus myocardin
The deduced amino acid sequence of the Xenopus laevis
myocardin protein is presented in Fig. 1, aligned with the
mouse and human myocardin protein sequences. Xenopus
myocardin contains 918 amino acids with a predicted
molecular mass of 101 kDa. We conclude that this protein
represents the Xenopus orthologue of myocardin for the
following reasons. First, Xenopus myocardin is 56% and 57%
identical to the mouse and human proteins, respectively, and
this level of sequence identity is similar to that of other
regulatory proteins in the cardiogenic pathway, such as Gata4
and Nkx2-5. Second, the sequence identity between Xenopus
myocardin and mouse myocardin-related factors, MRTF-A and
B (MKL1 and MKL2 – Mouse Genome Informatics), is only
32% and 31% respectively. Third, a search of the draft Xenopus
genomic sequence revealed no other genes with greater
similarity to mammalian myocardin. Finally, the basic region
of myocardin, which is involved in interactions with SRF
(Wang et al., 2001) and the SAP domain, which is thought to
function in chromatin remodeling (reviewed by Aravind and
Koonin, 2000) are both highly conserved between frog and
mouse (89% and 90%, respectively).
The expression pattern of myocardin during Xenopus
Fig. 1. Alignment of frog, mouse and human myocardin proteins. The basic region (involved in SRF binding), the SAP domain (involved in
chromatin remodeling), and the leucine zipper-like domain (dimerization domain), are labeled. The Xenopus myocardin protein is 56% and









development has been determined using whole-mount in situ
hybridization (Fig. 2). Myocardin transcripts are not detectable
in the early neurula embryo (stage 15; Fig. 2A) at a time when
transcripts for the precardiac marker, Nkx2-5, are abundant
(Fig. 2C). Myocardin expression is first detected in the late
neurula embryo (stage 24) in the pre-cardiac patches of anterior
lateral mesoderm (Fig. 2A’). This expression precedes, by
approximately 3 hours, detection of transcripts for myosin
heavy chain-α (MHCα) which is an early and robust marker
of myocardial differentiation in the Xenopus embryo. In the
mouse embryo, myocardin is co-expressed with Nkx2-5 in
early cardiac primordia (Wang et al., 2001) but this does not
appear to be the case in the frog embryo. At stage 27,
myocardin transcript levels continue to increase (Fig. 2A’’) and
MHCα transcripts are detectable in the differentiating cardiac
tissues (Fig. 2B’’). At this stage the domain of myocardin
expression appears identical to that of MHCα, but is
significantly more restricted than the Nkx2-5 expression
domain (Fig. 2A’’’,B’’’,C’’’). Myocardin expression persists
during subsequent cardiac development and is visible
throughout the atrial and ventricular
muscle layers of the tadpole heart (Fig.
2D). By the tadpole stage (stage 40),
myocardin transcripts are also visible in
visceral smooth muscle cells surrounding
the looping gut (Fig. 2E,F) and in isolated
smooth muscle precursor cells adjacent to
the forming dorsal aorta (Fig. 2F). Overall,
the expression of Xenopus myocardin in
developing cardiac and smooth muscle
tissues closely resembles the expression
profile reported for the murine myocardin
gene (Wang et al., 2001). Two additional
Xenopus myocardin-related sequences,
MRTF-A and MRTF-B have been reported
(Wang et al., 2002) and in situ
hybridization analysis of these sequences
is shown in Fig. 2G and H, respectively.
Neither gene shows detectable expression
in the cardiogenic region of the embryo, even when the
chromogenic detection reaction is continued until non-specific
background staining becomes evident. RT-PCR analysis
indicates that, surprisingly, myocardin, MRTF-A and MRTF-B
transcripts are all present at significant levels in the fertilized
egg, but transcripts decline to effectively undetectable levels by
the gastrula stage. RT-PCR analysis of isolated heart patch
tissue from the stage 28 embryo shows abundant expression of
myocardin but no detectable expression of MRTF-A or B (Fig.
2I). The absence of MRTF-A and B transcripts from the pre-
cardiac region is important for interpretation of morpholino
knockdown experiments described below.
Myocardin induces ectopic cardiac muscle gene
expression in whole embryos
Previous studies using cells in culture showed that myocardin
is able to activate reporter genes containing a range of
myocardial (Wang et al., 2001; Wang et al., 2002) and smooth
muscle promoters (Chen et al., 2002; Wang et al., 2003; Du et
al., 2003). Myocardin is also able to activate expression of
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Fig. 2. Developmental expression of Xenopus
myocardin and MRTF genes. The expression of
Xenopus myocardin (A-A’’’) was analyzed by
whole-mount in situ hybridization and
compared to the expression patterns of the
cardiac differentiation marker, MHCα (B-B’’’),
and the pre-cardiac marker, Nkx2-5 (C-C’’’) at
the stages indicated. Myocardin expression in
the stage 24 embryo is localized to the pre-
differentiation cardiac mesoderm in a more restricted domain than Nkx2-5, which is
also expressed in the pharyngeal arch region (compare A’ with C’). MHCα expression
is located in an identical domain to myocardin at stage 27 (compare A’’ with B’’). A’’’,
B’’’ and C’’’ are ventral views of the stage 27 embryos illustrated. (D) In the heart of a
stage 45 embryo myocardin expression is located throughout the myocardial layer of
the atrium (a), ventricle (v), and outflow tract (ot). (E) Myocardin is expressed in the
visceral smooth muscle in stage 42 embryos. (F) Higher magnification reveals
myocardin expression in individual smooth muscle cells adjacent the dorsal aortae and
in the smooth muscle layer of the gut. DA, dorsal aorta; SM, smooth muscle. (G, H) In
situ hybridization analysis of stage 27 embryos shows that the myocardin-related
transcription factors, MRTF-A and MRTF-B, are not expressed in the pre-cardiac
mesoderm (ventral views). (I) RT-PCR analysis of myocardin, MRTF-A and MRTF-B
expression in early Xenopus embryos and isolated heart patches from stage 28
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endogenous smooth muscle genes (Chen et al., 2002; Du et al.,
2003; Wang et al., 2003; Yoshida et al., 2003). We used the
Xenopus embryo as an in vivo model system to investigate the
potential of myocardin to regulate transcription of endogenous
cardiac and smooth muscle genes. In these experiments,
mRNA encoding myocardin was injected into single
blastomeres of eight-cell embryos. The uninjected side of the
embryo served as a negative control. At subsequent stages of
development, expression of cardiac or smooth muscle markers
was determined by in situ hybridization. Our results
demonstrate that myocardin is sufficient to induce precocious
and ectopic expression of cardiac markers. For example,
expression of the cardiac-specific differentiation marker,
MHCα, is normally initiated in the late neurula embryo (stage
25) and is undetectable at stage 14 (Fig. 3A). In embryos
injected with myocardin mRNA however, high levels of ectopic
MHCα transcripts were present in stage 14 embryos (Fig. 3B)
approximately 24 hours before expression would normally be
detected in the heart. Ectopic expression was observed in 65%
of myocardin-injected embryos (13/20). Similarly, precocious
and ectopic expression of cardiac α-actin was observed in
myocardin-injected embryos (Fig. 3D,E) as was somewhat
weaker expression of cardiac troponin I (cTnI), and the smooth
muscle marker SM22 (data not shown). Ectopic expression of
MHCα persisted through subsequent development, and
appeared to be particularly strong in neural tissues (Fig. 3G).
As shown in Fig. 3H, MHCα transcripts could be detected in
isolated patches, apparently within tissues of the eye and neural
tube. Examination of numerous sectioned embryos suggested
that ectopic expression of cardiac markers was limited to
ectodermal and mesodermal tissue layers because we never
observed cardiac gene transcripts in endoderm derivatives,
even when myocardin mRNA was specifically targeted to this
germ layer. Finally, despite extended culturing of myocardin
mRNA injected embryos, we never observed the presence of
beating tissue or striated muscle at ectopic locations in the
embryo.
While these embryo injection results show that myocardin
is capable of activating ectopic cardiac marker expression in
the embryo, it is important to note that not all cardiac
differentiation markers were induced. For example, we never
observed ectopic expression of myosin light chain-2 (MLC2)
transcripts in these embryos, which is surprising since the
MLC2 gene is regulated by SRF (Qasba et al., 1992; Latinkic
et al., 2004) and because myocardin activates the MLC2
promoter in cultured cells (Wang et al., 2001). The failure of
myocardin to activate MLC2 in Xenopus does not seem to be
a dose effect, since injection of greater amounts of myocardin
mRNA did not succeed in activating MLC2 expression.
Transgenic expression of myocardin activates
cardiac gene expression in neural tissues
When mRNA is injected into a Xenopus embryo, translation of
the mRNA commences almost immediately. In the experiments
described above, the embryos were injected at the eight-
cell stage, however, activation of the first tissue-specific
transcription pathways did not commence until approximately
the gastrulation stage of development (stage 10). It is possible
Fig. 3. Myocardin activates ectopic
expression of myocardial markers
in the Xenopus embryo. (A-H) 125
pg of myocardin mRNA was
injected into one cell of an eight-
cell embryo, which was then
assayed for cardiac markers by
whole-mount in situ hybridization.
No expression of the MHCα gene
is observed in uninjected stage 14
embryos (A), however widespread
transcription of MHCα is observed
in myocardin-injected embryos
(B). Similarly, cardiac α-actin is
observed specifically in the pre-
somitic mesoderm at stage 14
control embryos (C), while
myocardin injected embryos
display widespread expression of
cardiac α-actin on the side of
injection (D). (E) Section through
the embryo in D shows ectopic
cardiac α-actin expression
(arrows) in the ectodermal and
mesodermal tissue layers. Ectopic
cardiac marker expression is not
observed in endodermal tissues.
(F) MHCα expression is heart-
specific at stage 28 in un-injected control embryos, but myocardin overexpression, (G), causes MHCα transcription in ectopic locations. Arrows
indicate normal cardiac expression. (H) Section through the embryo in G shows patches of ectopic MHCα expression in the neural tube (nt) and
eye. (I) Fluorescence microscopy of a stage 29 Xenopus embryo co-transgenic for NβT-GFP and NβT-myocardin showing GFP expression in
neural tissues. (J) In situ hybridization analysis of NβT-GFP/NβT-myocardin co-transgenic embryos using a MHCα probe shows ectopic









therefore, that myocardin was only capable of initiating cardiac
gene expression ectopically, in the absence of competing
developmental programs. To address this issue, we generated
transgenic embryos in which transcription of myocardin
mRNA was driven by the neural β tubulin (NβT) promoter.
NβT is a neural differentiation marker that is specifically
expressed in the central and peripheral nervous system (Richter
et al., 1988) and an NβT-GFP transgene recapitulates the
endogenous expression pattern (Kroll and Amaya, 1996) (Fig.
3I). A neural promoter was chosen for these experiments
because Xenopus neural tissues express high levels of the
essential myocardin cofactor, SRF (data not shown) and
because we sought to determine whether myocardin was
capable of activating cardiac gene expression in cells derived
from the ectodermal germ layer. Embryos expressing
myocardin in neural tissues were assayed by in situ
hybridization for MHCα transcripts. As shown in Fig. 3J,
MHCα expression was activated throughout differentiated
neural tissues, in a pattern identical to that of the GFP marker
(Fig. 3I). Moreover, the level of MHCα expression in the neural
tube was comparable to the level of expression of the
endogenous gene in the heart. This result indicates that
myocardin is able to activate transcription of cardiac-specific
genes in tissues that are already specified to a neural fate.
Transgenic embryos expressing myocardin in neural tissues
developed normally and showed a full range of reflex
responses, suggesting that myocardin did not subvert normal
neural development.
Myocardin activates cardiac and smooth muscle
differentiation markers in animal cap explants
Since myocardin is able to activate cardiac tissue markers in
whole Xenopus embryos, we wished to assess its ability to
activate myocardial gene transcription in a more defined
system. Animal cap explants from the Xenopus embryo,
consisting entirely of naive ectodermal tissue, have been
widely used to investigate gene expression (Cascio and
Gurdon, 1987; Grainger and Gurdon, 1989; Howell and Hill,
1997; Tada et al., 1998) and are a convenient alternative to
cultured cells. Animal caps typically differentiate to form
epidermal tissue and never express cardiac genes (Fig. 4A, lane
labeled uninjected). Animal cap tissue contains a significant
amount of SRF mRNA (Fig. 4A) and so the essential
myocardin cofactor is present in these cells. The consequences
of expressing myocardin in animal cap explants was assayed
at stage 12.5, corresponding to the late gastrula stage and
approximately 24 hours before myocardial marker expression
would commence in the intact embryo. As shown in Fig. 4A,
myocardin precociously activates a range of myocardial
differentiation markers including MHCα, cTnI and cardiac α-
actin (which is also expressed in skeletal muscle). In addition,
myocardin activated expression of the smooth muscle
differentiation markers SM actin, calponin H1 and SM22 (Fig.
4A).
As in the whole embryo experiments, myocardin did not
activate expression of all myocardial genes. Of the markers
tested, MLC2 was never expressed in animal caps (Fig. 4A),
even when the dose of myocardin was increased approximately
fourfold over the amount sufficient to activate MHCα (data not
shown). SRF was not limiting in these experiments since co-
injection of SRF mRNA, together with myocardin mRNA, did
not alter the results (data not shown). It has been reported that
expression of Gata4 in animal cap explants is sufficient to
initiate the complete cardiac differentiation pathway, including
formation of beating tissue (Latinkic et al., 2003). In that study,
cardiac marker expression was first observed at about stage 28,
corresponding to the normal time at which cardiac markers are
observed in the intact embryo. To test whether more time might
be required for expression of MLC2 we also examined animal
cap explants cultured until stage 29-30. In all cases, the
expression of markers at stage 29 was identical to that observed
at stage 12.5, indicating that time of culture is not a significant
factor in these experiments (data not shown).
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Fig. 4. Myocardin induces transcription of endogenous cardiac and
smooth muscle marker genes in animal cap explants. Myocardin-
expressing animal pole explants were cultured until stage 12.5 and
assayed for cardiac and smooth muscle gene expression by RT-PCR.
(A) Uninjected animal caps differentiate into epidermal tissue and
never express mesodermal derivatives, including cardiac or smooth
muscle markers (lane labeled uninjected). Myocardin-injected caps
however, express a wide range of cardiac and smooth muscle
differentiation markers (lane labeled myocardin), including cardiac
α-actin, MHCα, cardiac TnI, SM22, calponin H1 and smooth muscle
actin. The myocardin cofactor SRF and the MADS box transcription
factor Mef2a, are upregulated in myocardin expressing caps. The
cardiogenic genes, Nkx2-5 and Gata4 are not expressed in
myocardin-injected animal caps. The lane labeled 12.5 WE,
represents the normal expression of the assayed genes in the whole
embryo at the time that the animal cap explants were assayed. (B)
Myocardin does not activate genes of the skeletal muscle or
mesodermal pathways. Myocardin-injected animal caps were
assayed by RT-PCR for the activation of mesodermal and skeletal
muscle markers. The general mesoderm marker brachyury (Xbra) is
not expressed in myocardin-injected caps. Furthermore, myocardin
does not activate expression of the skeletal muscle transcription
regulators, MyoD, Myf5, MRF4 and myogenin, or the skeletal
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These results suggest that, although myocardin is able to
precociously activate transcription of a subset of myocardial
markers, it is not sufficient to initiate the complete cardiac
development program. Investigation of the expression of other
cardiogenic genes supports this proposal. First, transcription of
the Nkx2-5 or Gata4 transcription factors was not activated in
response to myocardin (Fig. 4A). Both of these genes are
essential for normal cardiogenesis (Lyons et al., 1995; Tanaka et
al., 1999; Molkentin et al., 1997). We note, however, that
expression of SRF and the MADS box transcription factor,
Mef2A, were both activated in animal caps (Fig. 4A), indicating
that at least some cardiac regulatory factors lie downstream of
myocardin and may play a role in ectopic activation of cardiac
markers. Transcription of the myocardin gene itself, however,
was not activated in animal caps (data not shown), indicating that
myocardin does not directly regulate its own expression. We also
addressed the possibility that the marker gene expression
observed in response to myocardin might be due to activation of
the skeletal muscle pathway. This is particularly relevant for the
cardiac α-actin marker, which is expressed in both cardiac and
skeletal muscle tissues in the embryo. RT-PCR analysis showed
that no transcripts were present for the general mesoderm
marker, brachyury (Xbra), the myogenic determination genes
MyoD, Myf5, MRF4 or myogenin, nor for the skeletal muscle
marker, skMLC (Fig. 4B), demonstrating that the skeletal muscle
program was not activated in the animal cap explants.
Myocardin cooperates with cardiogenic factors to
regulate transcription
The failure to observe MLC2 transcription in animal caps was
unexpected since the MLC2 promoter is regulated by
myocardin in transfection assays using COS cells (Wang et al.,
2001). One possible explanation for these findings is that
activation of MLC2 expression may require transcription
factors, in addition to myocardin, that are not present in animal
cap cells. Therefore, we tested the ability of Gata4, Nkx2-5 and
Tbx5, all of which are important regulators of cardiac gene
expression (Durocher et al., 1997; Chen and Schwartz, 1996;
Lyons et al., 1995; Tanaka et al., 1999; Bruneau et al., 2001)
to cooperate with myocardin in activation of MLC2 expression.
Mixtures of mRNAs encoding all four factors were tested in
the animal cap assay at stage 12.5 (Fig. 5A). First, we observed
that co-expression of all four transcription factors succeeded in
activating expression of MLC2 (lane labeled M+N+G+T). This
activation was not observed using a mixture of the three
transcription factors in the absence of myocardin (lane marked
N+G+T). Second, the presence of all four transcription factors
did not significantly increase MHCα or SM22 expression levels
relative to myocardin alone, suggesting that the other factors
are not required for efficient expression of these genes in the
animal cap. Third, no beating tissue was observed in animal
caps co-expressing all four transcription factors, even when the
explants were cultured until the equivalent of stage 45,
approximately 5 days after a beating heart would form in the
intact embryo (data not shown). This result indicates that the
presence of this particular combination of factors is not
sufficient to activate the complete pathway leading to
myocardial differentiation. Testing of myocardin with different
combinations of transcription factors (Fig. 5B), revealed that
the expression of myocardin and Gata4 alone was sufficient to
activate MLC2 transcription in the animal cap. This result is
consistent with recent transgenic studies of the Xenopus MLC2
promoter that show essential roles for SRE and GATA
regulatory elements (Latinkic et al., 2004).
Myocardin loss of function by morpholino
knockdown results in a block to cardiac
differentiation
To determine whether myocardin is essential for expression of
cardiac genes in the developing embryo, we utilized the
antisense morpholino method for inhibition of translation of
specific mRNAs. It was only possible to examine cardiac
marker expression in these experiments because smooth
muscle differentiation occurs rather late in Xenopus
development (after about stage 35) and is therefore outside of
the window for morpholino interference (Heasman et al.,
2000). Two independent morpholinos, MO1 and MO2,
complementary to non-overlapping sequences within the 5′ end
of the Xenopus myocardin mRNA were prepared and control
experiments demonstrated that these effectively inhibited
translation of a myocardin fusion transcript in the embryo (Fig.
6A,B). Based on limited sequence conservation, neither of
these morpholinos is expected to inhibit translation of MRTF-
A or B. For loss-of-function experiments, MO1 was injected
into one cell of a two-cell embryo, so that the uninjected side
served as a stage-matched negative control. The injected
Fig. 5. Myocardin acts in combination with other cardiac
transcription factors to activate endogenous MLC2 expression in
animal cap explants. (A) Expression of myocardin alone (lane
labeled myocardin) activates SM22 and MHCα expression, but is not
sufficient to activate expression of the MLC2 gene. Expression of
Nkx2-5, Gata4, or Tbx5 alone, or the combination of these three
factors (lane labeled N+G+T) is not sufficient to activate expression
of MLC2 or SM22 or MHCa. However, when myocardin is
coexpressed with Nkx2-5, Gata4 and Tbx5, MLC2 gene expression is
activated (lane labeled M+N+G+T). M, myocardin; N, Nkx2-5; G,
Gata4; T, Tbx5. (B) Co-expression of combinations of transcription
factors in animal cap explants shows that any combination of









embryos were then raised until stage 28-29 when they were
assayed for cardiac marker gene expression by in situ
hybridization. Injection of 10 ng of MO1 resulted in a
significant inhibition of MHCα expression on the side of
injection (Fig. 6C and Table 1). Inhibition of MHCα expression
was observed in 57% of experimental embryos (13/23). Using
MLC2, an independent marker of cardiac differentiation,
inhibition was observed in 86% of embryos (42/49).
Asymmetry of cardiac marker expression was observed in only
4-5% of uninjected controls (Table 1). The independent
morpholino sequence, MO2, also inhibited expression of
MHCα and MLC2, although the efficiency was somewhat less
than that observed for MO1 (Table 1). In situ hybridization
detection of Nkx2-5 transcripts showed that expression of this
precardiac marker sequence was unaffected by myocardin MO
treatment (Fig. 6C). Similarly, Gata4 levels were not influenced
by the presence of the myocardin MO (data not shown). These
results indicate that precardiac tissues are still present in MO-
treated embryos and that the Nkx2-5 and Gata4 expression
pathways are independent of myocardin activity. Moreover,
transverse sections of control and myocardin MO-treated
embryos at the linear heart tube stage (st. 34) revealed that the
normal morphogenic movements associated with heart tube
formation (i.e. delamination) are disrupted on the MO-injected
side while the uninjected side of the embryo appears normal
(Fig. 6D). Overall, these loss-of-function studies show that
myocardin activity is essential for expression of cardiac
differentiation markers and for cardiac morphogenic
movements during Xenopus development.
Discussion
Myocardin activates endogenous expression of
cardiac differentiation markers
Several recent papers have emphasized the role of myocardin
as a regulator of the smooth muscle differentiation pathway,
but our results indicate that myocardin also plays a central role
in the pathway leading to myocardial development. During
Xenopus development, expression of myocardin is initially
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Table 1. Summary of myocardin morpholino phenotypes
Normal cardiac Reduced/ Number of 
Morpholino gene expression eliminated expression embryos
MHCα expression
Control 142 (95%) 8 (5%) 150
MO1 10 (43%) 13 (57%) 23
MO2 87 (64%) 48 (36%) 135
MLC2 expression
Control 48 (96%) 2 (4%) 50
MO1 7 (14%) 42 (86%) 49
MO2 29 (60%) 20 (40%) 49
Nkx2-5 expression
Control 49 (98%) 1 (2%) 50
MO1 50 (91%) 5 (9%) 55
MO2 20 (100%) 0 (0%) 20
Fig. 6. Inhibition of myocardin activity using
antisense morpholino (MO) oligos. (A,B)
Control experiment where myocardin MO1
inhibits translation of a transcript containing
the myocardin 5′UTR fused to the EGFP
coding region. mRNA (400 pg) was injected
into one-cell Xenopus embryos with or
without 10 ng of myocardin MO1 and the
embryos were then assayed for the presence
of GFP transcript and protein at stage 17. The
presence of MO1 did not affect the levels of
EGFP transcript as detected by RT-PCR (A)
but did significantly reduce the amount of
translated GFP protein as detected by western
blotting (B). (C) Xenopus embryos were
injected with 10 ng of myocardin MO1 into
one blastomere at the two-cell stage and
cultured until stage 29, when cardiac
differentiation markers are normally
expressed in the symmetric heart patches.
Uninjected control embryos (labeled C) or
myocardin MO1-injected embryos (labeled
MO) were assayed by in situ hybridization.
Myocardin MO1 inhibited expression of
MHCα and MLC2 on the side of injection
(right side of figure) but did not affect the
expression of Nkx2-5. (D) Sections through
the heart of uninjected (labeled C) and one-
sided MO1-injected (labeled MO) Xenopus
embryos at the linear heart tube stage (stage
34). Embryos were assayed by in situ
hybridization for expression of either MHCα
or Nkx2-5 transcripts to mark the location of
myocardial cells and to confirm a reduction in MHCα expression on the injected side (right side) of the MO-injected embryo. Uninjected
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detected in the cardiac primordia at stage 24, immediately prior
to the onset of expression of the earliest myocardial
differentiation markers (stage 25). The domain of myocardin
expression coincides precisely with that of the differentiation
markers (Fig. 2A). In contrast, several other important
myocardial regulatory factors, including Nkx2-5, Gata4 and
Tbx5 are expressed in precardiac tissues from approximately
the time of gastrulation onwards (Tonissen et al., 1994; Jiang
and Evans, 1996; Horb and Thomsen, 1999). Since no
expression of myocardial markers is observed until about 24
hours after gastrulation, it is clear that co-expression of these
factors alone is not sufficient to activate the cardiomyogenic
pathway in vivo. Based on the expression profile therefore,
it is highly likely that myocardin serves as an essential
intermediate in the pathway leading to myocardial
differentiation in the embryo.
Injection experiments show that expression of myocardin is
able to activate high levels of expression of myocardial marker
genes at ectopic locations in the Xenopus embryo (Fig. 3) or
in animal cap tissue (Fig. 4). Ectopic expression of marker
transcripts appeared to be most robust in neural tissues, but was
observed at a variety of locations in the embryo, with the
exception of endodermal tissue. Directed expression of
myocardin in neural tissues using the neural β-tubulin
promoter activated high levels of MHCα expression throughout
neural tissues as late as the swimming tadpole stage. This
indicates that myocardin is able to activate expression of at
least some myocardial markers in the absence of other cardiac-
specific transcription factors and without subverting pre-
existing regulatory pathways. In the animal cap assays,
myocardin initiated transcription of a number of smooth
muscle markers, including SM22, SM actin and CalpH1. This
is in agreement with previous studies that have demonstrated
the ability of myocardin to activate endogenous smooth muscle
genes in 10T1/2 fibroblasts and mouse embryonic stem cells
(Du et al., 2003). Myocardin also activated a range of different
myocardial marker genes in animal cap explants (Fig. 4). For
all of these differentiation markers, significant levels of
transcript had already accumulated by the gastrulation stage
(stage 12.5) much earlier than the earliest differentiation in the
intact embryo (stage 25). This observation suggests that
myocardin can over-ride the normal temporal program of
cardiac or smooth muscle development and cause the
immediate activation of target genes. It is important to note
however, that we never observed striated structures or beating
tissue at ectopic locations in the myocardin-injected embryos,
or in animal cap explants, indicating that myocardin alone is
not sufficient to activate the complete pathway leading to
myocardial differentiation in this context.
The observed ability of myocardin to cause ectopic
transcription of myocardial markers is not a common property
of cardiac transcription regulators. For example, numerous
experiments have attempted to activate marker expression in
the whole embryo or in animal cap explants, with Nkx2-5 and
GATA factors, either alone or in combination (Cleaver et al.,
1996; Chen and Fishman, 1996; Fu and Izumo, 1995; Jiang and
Evans, 1996). In all cases, marker gene expression was either
absent or extremely weak. Similarly, none of these
transcription factors were capable of activating detectable
expression of MHCα in our experiments. The recent
observation that Nkx2-5 is an upstream regulator of myocardin
(Ueyama et al., 2003) suggests that instances where Nkx2-5
overexpression successfully triggered cardiac marker
expression (Chen and Fishman, 1996; Fu and Izumo, 1995)
may have occurred via myocardin activation. An important
exception to the preceding discussion is the recent observation
that Gata4 is capable of generating beating cardiac tissue in
animal cap explant cultures (Latinkic et al., 2003). In this case
however, induction of the cardiogenic program requires nearly
10-fold higher levels of Gata4 mRNA than the amounts of
myocardin mRNA used in our experiments (Figs 4, 5) and
differentiation marker expression only occurs after extended
culture. A plausible explanation for these results is that Gata4
initiates a cascade of events resulting in cardiac differentiation,
while myocardin directly switches on transcription from target
promoters.
Myocardin cooperates with other cardiac regulatory
factors
Although several cardiac marker genes were transcriptionally
activated in response to myocardin expression in embryos and
animal caps, we were never able to detect expression of the
MLC2 gene. This is surprising since myocardin is able to
activate transcription from the MLC2 promoter in COS cells
(Wang et al., 2001; Wang et al., 2002). Previous studies have
shown that transcription of myocardial genes is often regulated
by cooperative interactions between transcription factors. For
example, interactions between SRF, Nkx2-5, Gata4 and Tbx5
are known to be important for maximal expression from the
ANF and cardiac α-actin promoters (Chen and Schwartz,
1996; Durocher and Nemer, 1998; Lee et al., 1998; Bruneau et
al., 2001). Our experiments show that interactions with other
transcription factors may also be important for myocardin
activity, since co-expression of Gata4 with myocardin results
in the induction of MLC2 expression (Fig. 5). Although this
observation is consistent with direct interactions of the
myocardin and Gata4 proteins, we cannot exclude the
possibility that Gata4 activates expression of other
transcription factor(s), which then cooperate with myocardin
to regulate MLC2. Previous studies have suggested that
dimerization of myocardin is required for transcriptional
activity, and that dimerization is facilitated by the presence of
multiple SRF binding sites (CArG boxes), in the target
promoter (Wang et al., 2003). We note that the Xenopus MLC2
gene contains two CArG boxes in the promoter region
(Latinkic et al., 2004), but that, in this instance, myocardin
requires cooperation with Gata4 to activate transcription from
the MLC2 promoter.
Myocardin loss-of-function and the genetic pathway
to heart development
Previous studies using dominant negative versions of
myocardin in Xenopus embryos resulted in the elimination of
heart differentiation (Wang et al., 2001) suggesting an essential
role for myocardin in cardiac development. However, mouse
embryos lacking myocardin activity develop a fairly normal
heart and die of vascular defects, presumably resulting from
loss of vascular smooth muscle differentiation (Li et al., 2003).
The relatively mild cardiac phenotype in the myocardin
knockout mouse could be due to redundancy with the
myocardin related factors (MRTF-A and MRTF-B), which are









transcriptional properties (Wang et al., 2002). Since the MRTF-
A and MRTF-B orthologues are not expressed in the
developing Xenopus heart (Fig. 2G-I) we were able to use
antisense morpholino knockdown methods to determine the
role of myocardin in heart development, in the absence of
rescuing activities. In these experiments, expression of the
myocardial markers, MHCα and MLC2 was dramatically
reduced or eliminated using two different morpholinos (Fig.
6C and Table 1). This result is consistent with previous
experiments in which expression of a dominant negative form
of myocardin eliminated cardiac differentiation in the Xenopus
embryo (Wang et al., 2001). Furthermore, myocardin MO-
treated embryos show disruption of the normal morphological
movements associated with heart tube formation (Fig. 6D).
Overall, these results indicate an essential role for myocardin
in Xenopus heart development and suggest that cardiogenesis
in myocardin-null mice is partially rescued by redundant
activities of MRTF-A and/or MRTF-B.
One of the unresolved questions relating to myocardin
activity is the mechanism by which tissue-specific expression
of target genes is regulated. In relatively naïve cells like
Xenopus animal cap cells (Fig. 4) or mouse ES cells (Du et al.,
2003), myocardin activates transcription of both cardiac and
smooth muscle genes. Depending on the particular cell line in
which myocardin is expressed, a different profile of smooth
muscle and cardiac differentiation markers may be activated
(Chen et al., 2002; Du et al., 2003; Wang et al., 2003). During
normal embryonic development however, activation of
myocardin target genes appears to be almost completely tissue
specific. For example, expression of the smooth muscle marker,
SM22, is never observed in the heart of Xenopus embryos (data
not shown), but SM22 expression is highly activated by
myocardin in Xenopus animal cap cells, together with a
number of myocardial markers. Other authors have previously
proposed that myocardin interacts with additional, tissue-
specific transcription factors to modulate, either positively or
negatively, its transcriptional activity (Du et al., 2003; Ueyama
et al., 2003; Wang et al., 2003). It is interesting to observe
therefore, that co-expression of myocardin with three
additional cardiogenic transcription factors, Gata4, Nkx2-5 and
Tbx5, in animal cap explants activated expression of both
cardiac and smooth muscle markers (Fig. 5A). This result
implies that none of these transcription factors is sufficient for
suppression of smooth muscle gene expression in the heart.
Identification of the proteins that help to specify myocardin
target selection will be a key step towards understanding the
cardiac and smooth muscle regulatory pathways.
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